These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

821 related items for PubMed ID: 21619378

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

  • 6. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM.
    Circulation; 2015 Oct 27; 132(17):1648-66. PubMed ID: 26503748
    [Abstract] [Full Text] [Related]

  • 7. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L, Peng H, Xu D, Zhao S.
    Pharmacol Res; 2013 Jul 27; 73():27-34. PubMed ID: 23578522
    [Abstract] [Full Text] [Related]

  • 8. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL.
    Nutr Metab Cardiovasc Dis; 2011 Nov 27; 21(11):835-43. PubMed ID: 21943799
    [Abstract] [Full Text] [Related]

  • 9. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A, Demir K, Altunkeser BB.
    Turk Kardiyol Dern Ars; 2014 Oct 27; 42 Suppl 2():56-67. PubMed ID: 25693363
    [Abstract] [Full Text] [Related]

  • 10. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ, Li JJ.
    Clin Chim Acta; 2014 Apr 20; 431():148-53. PubMed ID: 24518357
    [Abstract] [Full Text] [Related]

  • 11. Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
    Hooper AJ, Burnett JR.
    Expert Opin Biol Ther; 2013 Mar 20; 13(3):429-35. PubMed ID: 23240807
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM, Dorsch MP, Bleske BE.
    Pharmacotherapy; 2013 Apr 20; 33(4):447-60. PubMed ID: 23553812
    [Abstract] [Full Text] [Related]

  • 13. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H, Burns TL, Hilleman DE.
    Cardiovasc Ther; 2014 Apr 20; 32(2):82-8. PubMed ID: 24354905
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
    Marais AD, Kim JB, Wasserman SM, Lambert G.
    Pharmacol Ther; 2015 Jan 20; 145():58-66. PubMed ID: 25046268
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang E.
    Clin Pharmacol Ther; 2015 Dec 20; 98(6):590-601. PubMed ID: 26369501
    [Abstract] [Full Text] [Related]

  • 19. Update of Clinical Trials of Anti-PCSK9 Antibodies.
    Wu NQ, Li S, Li JJ.
    Cardiovasc Drugs Ther; 2015 Apr 20; 29(2):159-69. PubMed ID: 25916406
    [Abstract] [Full Text] [Related]

  • 20. PCSK9 inhibition: current concepts and lessons from human genetics.
    Rodriguez F, Knowles JW.
    Curr Atheroscler Rep; 2015 Mar 20; 17(3):487. PubMed ID: 25637042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.